Public Procurement of Medicines in Europe: Key Findings and Best Practices
Experts in the Pharmacoeconomics Department recently conducted a study on the best practices in the public procurement of medicines. Commissioned by the European Commission, this study aims to improve access to medicines, affordability, availability, and more.
Public procurement of medicines can improve access, foster competition, and address important policy objectives. This study mapped and analyzed PPM practices across 32 European countries, revealing some fascinating insights.
Findings include:
- Different organizational forms of procurement, ranging from facility-based to centralized procurement.
- Use of various procedures and techniques, including the Most Economically Advantageous Tender
- Specific forms of procurement in the hospital sector
- Impacts on policy objectives, such as access to medicines and environmental protection
- Best practices for optimizing PPM in Europe
Discover the full report for a comprehensive understanding of PPM practices in Europe on the below link. Let’s work together to ensure affordable and accessible medicines for all!
Recent Posts
Rare Medications Coverage in the Netherlands: Price Reductions Required
Zorginstituut Nederland has announced that two rare disease medications, exagamglogene autotemcel (Casgevy®) and omaveloxolon (Skyclarys®), will only be covered by Dutch basic health insurance if their prices drop significantly. For omaveloxolon, treating Friedreich's ataxia, an 84% price cut is ...
Sanofi’s Rilzabrutinib Receives Orphan Designation for IgG4-Related Disease
Sanofi's rilzabrutinib has received orphan drug designation from the European Medicines Agency for treating IgG4-related disease (IgG4-RD). This reversible covalent Bruton's tyrosine kinase (BTK) inhibitor earned the designation based on promising Phase 2 study results. The findings, presented at...
PADCEV KEYTRUDA Urothelial Cancer: Advancements in Survival Outcomes and Economic Impact
A newly published Pfizer press release presents clinical trial results indicating that the combination therapy PADCEV™ (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) significantly improves overall survival in patients with previously untreated locally advanced or metastatic urothelial c...